What's new

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Date of authorisation: 26/09/2017, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Date of authorisation: 26/09/2017, Revision: 40, Status: Authorised

Mar 25, 2025 - 17:21
 0
Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Date of authorisation: 26/09/2017, Revision: 40, Status: Authorised
Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Date of authorisation: 26/09/2017, Revision: 40, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, ...

Next Article

Taste Radio: Why A Financial Windfall Won’t Fulfill Caulipower’s Gail Becker…Or ...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 17, 2025  0

European Shortages Monitoring Platform (ESMP) User guid...

Mar 10, 2025  0

Human medicines European public assessment report (EPAR): Memantine Mylan, memantine, Date of authorisation: 21/04/2013, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 20, 2025  0